ArticleAging clinical and experimental research2025
Regular glucosamine supplementation and risk of age-related chronic diseases: evidence from a propensity score-matched cohort study.
Article in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glucosamine Use and Its Association with Colorectal Cancer and Mortality: A Systematic Review and Meta-Analysis.Journal of Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlucosamine is a widely used dietary supplement, particularly among middle-aged and older adults, with potential health benefits beyond joint health. However, its potential role in the prevention of chronic diseases remains uncertain.
aimsTo investigate the association between regular glucosamine use and the risk of age-related non-communicable diseases (NCDs) in a large prospective cohort.
methods269,033 participants in the large prospective cohort (UK Biobank) without NCDs at baseline were included. 1:1 propensity-score matching (PSM) was used to match glucosamine users with non-users. Cox proportional hazard regression was used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs).
resultsDuring a median follow-up of 13.8 years, 52,556 participants reported regular glucosamine use. After PSM, 52,525 users and 52,525 non-users were included in the matched cohort. After false discovery rate correction, regular glucosamine use was associated with a significantly lower risk of seven NCDs: esophageal cancer (HR, 0.73; 95% CI, 0.58-0.92), gout (HR, 0.81; 95% CI, 0.72-0.91), chronic obstructive pulmonary disease (HR, 0.86; 95% CI, 0.80-0.93), colorectal cancer (HR, 0.86; 95% CI, 0.78-0.94), chronic liver disease (HR, 0.87; 95% CI, 0.80-0.94), heart failure (HR, 0.88; 95% CI, 0.81-0.96), and coronary heart disease (HR, 0.92; 95% CI, 0.88-0.96).
conclusionsRegular use of glucosamine was associated with a reduced risk of several age-related chronic diseases. Further studies are needed to confirm these findings and to clarify its potential role in supporting healthy aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.